Show simple item record

dc.contributor.authorSanguanini, Men
dc.date.accessioned2018-07-18T09:24:33Z
dc.date.available2018-07-18T09:24:33Z
dc.date.issued2018-05-01en
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/278219
dc.description.abstractCRISPR/Cas9 is a gene editing technology that is revolutionising the way that scientists design biomedical research. In addition to this, CRISPR/Cas9 is opening promising avenues for applications in gene therapy, manufacturing, and agriculture. The commercial and disruptive potential of this invention is so promising that it sparked a ‘gold rush’ towards patenting CRISPR/Cas technologies. Two principal players weighed in to define the CRISPR/Cas9 patent landscape in the US: the University of California Berkeley (UCB) and the Broad Institute, a joint MIT-Harvard research institute. This ultimately led to a high-profile patent battle in front of the US Patent Trial and Appeal Board, where the Broad Institute prevailed in the first instance. The dispute, however, continues worldwide. In this Communication, I will focus on the European front of this litigation; the problem being not only who owns this technology in Europe, but also what are the potential impacts of patent conflicts between academic institutions on European policy and law.en
dc.publisherCUSPEen
dc.subjectIntellectual propertyen
dc.subjectCRISPR/Cas9en
dc.titleA Cutting-edge IP Litigation: the European Front of CRISPR Patent Waren
dc.typeWorking Paper
prism.publicationDate2018en
prism.publicationNameCUSPE Communicationsen
dc.identifier.doi10.17863/CAM.25563
rioxxterms.versionofrecord10.17863/CAM.25563en
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2018-05-01en
rioxxterms.typeWorking Paperen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record